Next Issue
Volume 4, January
Previous Issue
Volume 3, June
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.1
0.9
Journals
Hematology Reports
Volume 3
Issue s3
share announcement
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 3, Issue s3 (December 2011) – 7 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
3 pages, 76 KiB  
Article
Case Studies of Elderly Patients with Non-Hodgkin's Lymphoma
by Stefano Luminari and Massimo Federico
Hematol. Rep. 2011, 3(s3), e7; https://doi.org/10.4081/hr.2011.s3.e7 - 28 Oct 2011
Cited by 2
Abstract
The treatment of patients with non- Hodgkin’s lymphoma (NHL) is often the treatment of elderly patients, as most patients are older than 65 years at diagnosis. These elderly patients present particular therapeutic challenges, because they may be more frail and at greater risk [...] Read more.
The treatment of patients with non- Hodgkin’s lymphoma (NHL) is often the treatment of elderly patients, as most patients are older than 65 years at diagnosis. These elderly patients present particular therapeutic challenges, because they may be more frail and at greater risk of treatment-related toxicity, especially anthracycline-related cardiotoxicity, than younger patients. The following two case studies illustrate the challenges and therapeutic decision-making in managing elderly patients with an aggressive and an indolent form of lymphoma.
Full article
4 pages, 187 KiB  
Article
SIOG (International Society of Geriatric Oncology) Recommendations for Anthracycline Use in the Elderly
by Matti Aapro
Hematol. Rep. 2011, 3(s3), e6; https://doi.org/10.4081/hr.2011.s3.e6 - 28 Oct 2011
Cited by 8
Abstract
A taskforce of the International Society of Geriatric Oncology (SIOG) has recently submitted recommendations on the use of anthracyclines in elderly patients. Despite the aging of the population and the high proportion of elderly individuals in the population of patients with non-Hodgkin’s lymphoma, [...] Read more.
A taskforce of the International Society of Geriatric Oncology (SIOG) has recently submitted recommendations on the use of anthracyclines in elderly patients. Despite the aging of the population and the high proportion of elderly individuals in the population of patients with non-Hodgkin’s lymphoma, the development of specialist expertise in the treatment of elderly patients with cancer is relatively recent. Treatment of the elderly is complex because they are a highly heterogeneous population, with large variations in health status, comorbidities and life expectancy. In addition, these patients are generally more susceptible than young patients to the cardiotoxic effects of anthracyclines. Strategies for assessing elderly patients with cancer, reducing the risk of congestive heart failure, and assessing the cardiotoxic effects of treatments are discussed. In addition, a summary of the SIOG recommendations is presented.
Full article
2 pages, 71 KiB  
Article
Ongoing Trials in Low-Grade Lymphoma
by Alexander Burchardt
Hematol. Rep. 2011, 3(s3), e5; https://doi.org/10.4081/hr.2011.s3.e5 - 28 Oct 2011
Abstract
There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemo-therapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems [...] Read more.
There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemo-therapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems to be rituximab combined with cyclo phosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Substitution of liposomal doxorubicin in place of conventional doxorubicin may improve outcomes in this indication, although evidence for its use in low-grade lymphoma is not as relevant as in aggressive lymphoma. Bendamustine, in combination with rituximab, has shown very good efficacy and tolerability in several lymphoma types, particularly follicular lymphoma and other low-grade lymphomas. Other combinations, such as those including bortezomib and lenalidomide, are under investigation in low-grade lymphoma, and the duration of rituximab maintenance therapy following bendamustine−rituximab-containing induction is being researched by the German Study Group for Indolent Lymphoma (StiL).
Full article
4 pages, 185 KiB  
Article
Anthracyclines: A Cornerstone in the Management of Non-Hodgkin’s Lymphoma
by Stefano Luminari, Antonella Montanini and Massimo Federico
Hematol. Rep. 2011, 3(s3), e4; https://doi.org/10.4081/hr.2011.s3.e4 - 28 Oct 2011
Cited by 17
Abstract
Since anthracyclines were introduced in the treatment of non-Hodgkin’s lymphoma in the late 1960s, they have been acknowledged as a cornerstone in the management of the disease and, in particular, of aggressive lymphomas. The high efficacy of anthracycline-containing regimens must, however, be balanced [...] Read more.
Since anthracyclines were introduced in the treatment of non-Hodgkin’s lymphoma in the late 1960s, they have been acknowledged as a cornerstone in the management of the disease and, in particular, of aggressive lymphomas. The high efficacy of anthracycline-containing regimens must, however, be balanced against the drug-related toxicity, which mainly affects the cardiovascular system and represents a major concern for clinicians, especially in the treatment of elderly patients. Patients’ outcomes could be further improved, particularly for those at high risk of cardiotoxicity, by substituting liposomal doxorubicin for conventional doxorubicin. This approach has already been tested and shown to be effective in several cancers, especially in different subsets of patients with diffuse large B-cell lymphoma. The use of liposomal doxorubicin in combination regimens for other conditions, such as follicular lymphoma and splenic marginal zone lymphoma, is also under investigation, and early results are promising.
Full article
3 pages, 145 KiB  
Article
Current Approaches to the Treatment of Non-Hodgkin's Lymphoma
by Christian Gisselbrecht
Hematol. Rep. 2011, 3(s3), e3; https://doi.org/10.4081/hr.2011.s3.e3 - 28 Oct 2011
Cited by 1
Abstract
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has long been a standard treatment for lymphoma. Improvements to the efficacy of this regimen can be made by increasing the doses of doxorubicin and cyclophosphamide, as in the chemotherapeutic regimen of doxorubicin, cyclophosphamide, vindesine, [...] Read more.
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has long been a standard treatment for lymphoma. Improvements to the efficacy of this regimen can be made by increasing the doses of doxorubicin and cyclophosphamide, as in the chemotherapeutic regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP), and by reducing the standard dosing interval, as seen with the CHOP-14 regimen. Adding the immunotherapeutic agent rituximab (R) to either CHOP or ACVBP has been shown to improve outcomes significantly, such that six cycles of R-CHOP plus two cycles of rituximab are as effective as eight cycles of R-CHOP, and R-CHOP-21 appears to be at least as effective as the more dose-intense R-CHOP-14. In patients who have several adverse prognostic factors, RACVBP plus autologous stem-cell transplantation has been shown to produce good treatment outcomes. The use of positron emission tomography scanning before and early in treatment should allow prediction of long-term outcomes, and therefore the adaptation of treatment to individual prognosis and treatment needs. In patients with follicular lymphoma, rituximab has been shown to improve the efficacy of conventional chemotherapies. In addition, rituximab alone or yttrium-90-ibritumomab tiuxetan are effective maintenance therapies in this condition.
Full article
3 pages, 166 KiB  
Article
The Use of Molecular Profiling for Diagnosis and Research in Non-Hodgkin's Lymphoma
by Miguel Angel Piris
Hematol. Rep. 2011, 3(s3), e2; https://doi.org/10.4081/hr.2011.s3.e2 - 28 Oct 2011
Abstract
Molecular profiling facilitates the understanding of the genetic processes underlying the development of cancer, and makes it possible to use specific signatures to prognosticate clinical outcome and to predict response to specific treatments. There has been a great increase in the availability of [...] Read more.
Molecular profiling facilitates the understanding of the genetic processes underlying the development of cancer, and makes it possible to use specific signatures to prognosticate clinical outcome and to predict response to specific treatments. There has been a great increase in the availability of tools for exploring genetic abnormalities in cancer cells, which have allowed a more comprehensive characterization of the mutations, translocations, and copy-number variations that may affect the development of cancer or therapy response. An improved understanding of the molecular basis of cancer is helping also in the identification of new molecular targets for therapy.
Full article
3 pages, 132 KiB  
Article
Moving forward with New Data and Approaches: A Fresh Look at Anthracyclines in Non-Hodgkin’s Lymphoma
by Dino Amadori
Hematol. Rep. 2011, 3(s3), e1; https://doi.org/10.4081/hr.2011.s3.e1 - 28 Oct 2011
Cited by 1
Abstract
Anthracyclines have a central role in the management of non-Hodgkin’s lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy [...] Read more.
Anthracyclines have a central role in the management of non-Hodgkin’s lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Previous Issue
Next Issue
Back to TopTop